Ganglionic blocking agents : with special reference to the effect of hexamethonium on the cardiovascular system / by W.D.M. Paton.

  • William Paton
Date:
[1952?]
Catalogue details

Licence: In copyright

Credit: Ganglionic blocking agents : with special reference to the effect of hexamethonium on the cardiovascular system / by W.D.M. Paton. Source: Wellcome Collection.

    6/6
    but is much less effective as a vasoconstrictor. It would be useful to know whether interruption of autonomic activity with hexamethonium would relieve or accentuate the migrainous attack. 5. Conclusion Ganglion blocking agents are pharmacologically a some¬ what novel type of drug in therapeutics, and the techniques of handling them are still being evolved. It is highly probable that hexamethonium will be replaced by more satisfactory agents, although none offering any substantial advantage has yet appeared; but the lessons learned with hexa¬ methonium should be applicable without serious modification References Arnold, P., Goetz, R. H. & Rosenheim, M. L. (1949) Lancet, 2, 408 Arnold, P. & Rosenheim, M. L. (1949) Lancet, 2, 321 Barnett, A. J. (1951) Lancet, 1, 1415 Burt, C. C. & Graham, A. J. P. (1950) Brit. med. J. 1, 455 Campbell, A. & Robertson, E. (1950) Brit. med. J. 2, 804 Campbell, A. J. M., Graham, J. G. & Maxwell, R. D. H. (1952) Brit. med. J. 1, 251 Dale, H. H. & Laidlaw, P. P. (1919) /. Physiol. 52, 355 Enderby, G. E. H. (1950) Lancet, 1, 1145 Enderby, G. E. H. et al. (1951) Discussion in: Proc. R. Soc. Med. 44, 829 Enderby, G. E. H. & Pelmore, J. F. (1951) Lancet, 1, 663 Finnerty, F. A. & Freis, E. D. (1950) Circulation, 2, 828 Finnerty, F. A. & Freis, E. D. (1951) New Engl. J. Med. 245, 325 Freis, E. D. (1951) Med. Ann. Distr. Columbia, 20, 297 Freis, E. D„ Stanton, J. R., Finnerty, F. A., Schnaper, H. W., Johnson, R. L., Rath, C. E. & Wilkins, R. W. (1951) J. clin. Invest. 30, 435 Grob, D. & Harvey, A. M. (1950) Bull. Johns Hopk. Hosp. 87, 616 Guiot, G., Damoiseau, P. & Poloukhine, N. (1951) Anesth. Analg., Paris, 8, 483 Harper, J. K. (1951) Brit. med. J. 1, 1262 Hughes, G. (1951) Lancet, 1, 666 Kay, A. W. & Smith, A. N. (1951) Gastroenterology, 18, 503 Kilpatrick, J. A. & Smirk, F. H. (1952) Lancet, 1, 8 Lewis, I. (1951) Lancet, 2, 150 Locket, S., Swann, P. G. & Grieve, W. S. M. (1951) Brit. med. J. 1, 778 Locket, S., Swann, P. G., Grieve, W. S. M. & Player, H. P. (1952) Brit. med. J. 1, 254 to the use of other drugs acting in the same way. In the meantime its purity of action, restricted to a remarkable degree to autonomic ganglia, makes the technique of gan¬ glionic block with hexamethonium worth careful study, and one the results of which provide fairly clear-cut information. Finally it may be noticed that with the aid of ganglion blocking drugs many stimulating observations in human physiology and pathology have been made, such as the fact that a low blood pressure can be safely maintained without producing “ shock ”, and that in the hypertensive patient tolerance to hexamethonium develops. It may be in these observations, as much as in any immediate clinical usefulness, that the importance of ganglion blocking agents will ultimately be found to lie. Mackey, W. A. & Shaw, G. B. (1951) Brit. med. J. 2, 259 Miles, B. E., Wardener, H. E. de, Churchill-Davidson, H. C. & Wylie, W. D. (1952) Clin. Sci. 11, 73 Milne, G. E. & Oleesky, S. (1951) Lancet, 1, 889 Murphy, E. A. (1951) Lancet, 2, 899 Paton, W. D. M. (1951) Brit. med. J. 1, 773 Paton, W. D. M. & Perry, W. L. M. (1951a)/. Physiol. 112, 49P Paton, W. D. M. & Perry, W. L. M. (1951b)/. Physiol. 114,41P Paton, W. D. M. & Zaimis, E. J. (1948) Nature, Lond. 162, 810 Paton, W. D. M. & Zaimis, E. J. (1949) Brit. J. Pharmacol. 4, 381 Paton, W. D. M. & Zaimis, E. J. (1951) Brit. J. Pharmacol. 6,155 Paton, W. D. M. & Zaimis, E. J. (1952) Pharmacol. Rev. 4 (In press) Penny, C. J. & Shackleton, R. P. W. (1951) Lancet, 2, 617 Restall, P. A. & Smirk, F. H. (1950) N.Z. med. J. 49, 206 Restall, P. A. & Smirk, F. H. (1951) Proc. Univ. Otago med. Sch. 29, 10 Rollason, W. N. (1951) Brit. med. J. 1, 1447 Rose, J. C. & Wemple, J. N. (1951) U.S. armed Forces med. J. 2, 937 Rosenheim, M. L. (1952) Proc. R. Soc. Med. 45, 269 Savile, S. (1950) Lancet, 2, 358 Schnaper, H. W., Johnson, R. L., Tuohy, E. B. & Freis, E. D. (1951) J. clin. Invest. 30, 786 Shackleton, R. P. W. (1951) Brit. med. J. 1, 1054 Smirk, F. H. & Alstad, K. S. (1951) Brit. med. J. 1, 1217 Turner, R. W. D. (1951) Practitioner, 167, 541 Vourc’h, G. (1952) Gaz. med. France, 59, 163 Werko, L., Frisk. A. R., Wade, G. & Eliasch, H. (1951) Lancet, 2, 470 Wien, R. & Mason, D. F. J. (1951) Brit. J. Pharmacol. 6, 611 Young, I. M. (1952) J. Physiol. 116, 4P Young, I. M., Wardener, H. E. de & Miles, B. E. (1951) Brit, med. J. 2, 1500 PRINTED IN GREAT BRITAIN BY SPOTTISWOODE, BALLANTYNE AND CO. LTD., LONDON AND COLCHESTER
    digitised image 1
    digitised image 2
    digitised image 3